The shadow of generic competition has long loomed around copyright’s iconic drug, Viagra, sparking questions about the prospects of similar pharmaceutical holdings. While initial years saw significant returns, the patent lapse has created the way for discounted substitutes, potentially lowering profitability and creating a real hazard for investo